# Euclises Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/euclises-pharmaceuticals

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.euclises.com
- Total disclosed funding: $2.6M
- Latest round: Series A (Aug 2, 2017)
- Investors on record: 8

## About

Based in Missouri, US, Euclises Pharmaceuticals operates as a clinical-stage biopharmaceutical company that develops oral, small-molecule drugs that target COX-2 to disrupt the tumor microenvironment and kill cancer cells. The company was Co-founded by John Talley and others. In April 2015, Euclises raised USD 2 million in Series A funding led by Cultivation Capital, St. Louis Arch Angels, and BioGenerator. As of 2022, the company is led by its president and CEO Bobby W. Sandage, Jr.

The company develops oral, small-molecule drugs that target COX-2 to disrupt the tumor microenvironment and kill cancer cells. When combined with immune checkpoint inhibitors by eliminating COX-2/PGE-2 mediated tumor immune evasion, the molecule shows monotherapy to slow tumor growth and completely regress tumors.

## Funding rounds

- Series A, Aug 2, 2017 — Argonautic Ventures
- Series A, Apr 7, 2015, $2M — BioGeneration Ventures, Cultivation Capital, St. Louis Arch Angels
- Series A, Sep 9, 2014, $0.6M — ABC Laboratories, Inc., BioGenerator, Missouri Technology Corporation, Cultivation Capital, St. Louis Arch Angels, Helix Fund

## Investors

- ABC Laboratories, Inc. — Series A
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series A
- Missouri Technology Corporation — Series A
- Cultivation Capital (https://capitalatlas.ai/funds/cultivation-capital) — Series A
- St. Louis Arch Angels — Series A
- Helix Fund — Series A
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series A
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A